New Relic, Inc. (NEWR) Reaches $94.63 High on May, 20; Shorts at Jazz Pharmaceuticals Plc – Ordinary Shares (JAZZ) Raised By 11%

May 20, 2018 - By Darrin Black

New Relic, Inc. (NYSE:NEWR) Logo

Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) had an increase of 11% in short interest. JAZZ’s SI was 1.47M shares in May as released by FINRA. Its up 11% from 1.32M shares previously. With 465,000 avg volume, 3 days are for Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ)’s short sellers to cover JAZZ’s short positions. The SI to Jazz Pharmaceuticals Plc – Ordinary Shares’s float is 2.51%. The stock increased 1.52% or $2.5 during the last trading session, reaching $167.51. About 427,218 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 0.32% since May 20, 2017 and is downtrending. It has underperformed by 11.87% the S&P500.

The stock of New Relic, Inc. (NYSE:NEWR) reached all time high today, May, 20 and still has $98.42 target or 4.00% above today’s $94.63 share price. This indicates more upside for the $5.25 billion company. This technical setup was reported by Barchart.com. If the $98.42 PT is reached, the company will be worth $209.84 million more. The stock increased 4.99% or $4.5 during the last trading session, reaching $94.63. About 1.85M shares traded or 223.97% up from the average. New Relic, Inc. (NYSE:NEWR) has risen 104.05% since May 20, 2017 and is uptrending. It has outperformed by 92.50% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $10.05 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 21.04 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Among 23 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 19 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Jazz Pharmaceuticals had 84 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Hold” rating by H.C. Wainwright given on Friday, August 25. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Wednesday, November 8 by RBC Capital Markets. The rating was maintained by RBC Capital Markets on Tuesday, June 27 with “Buy”. The company was maintained on Sunday, December 10 by Cantor Fitzgerald. As per Wednesday, June 7, the company rating was maintained by Cowen & Co. BMO Capital Markets maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Thursday, January 11. BMO Capital Markets has “Buy” rating and $196.0 target. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Wednesday, June 7 by BMO Capital Markets. The company was upgraded on Monday, April 25 by SunTrust. BMO Capital Markets maintained the shares of JAZZ in report on Wednesday, February 28 with “Outperform” rating. Mizuho maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Wednesday, February 24 with “Neutral” rating.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Bizjournals.com which released: “Peninsula drug maker swings $110 million deal for voucher” on April 30, 2018, also Bizjournals.com with their article: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” published on May 17, 2018, Fool.com published: “3 Top Biotech Stocks to Buy in May” on May 09, 2018. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Seekingalpha.com and their article: “Jazz Pharmaceuticals Plc (JAZZ) Q1 2018 Results – Earnings Call Transcript” published on May 09, 2018 as well as Prnewswire.com‘s news article titled: “Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences” with publication date: May 09, 2018.

Since December 11, 2017, it had 0 insider purchases, and 21 selling transactions for $4.95 million activity. WILSON KAREN J had sold 3,899 shares worth $604,345 on Tuesday, April 10. On Friday, March 9 COZADD BRUCE C sold $150,000 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 1,000 shares. ENRIGHT PATRICK G had sold 9,000 shares worth $1.26M. Young Matthew P. sold $460,381 worth of stock. 200 shares were sold by MILLER MICHAEL PATRICK, worth $29,730 on Friday, January 12. Shares for $122,446 were sold by Treacy Paul on Thursday, March 1.

Investors sentiment increased to 1.09 in Q4 2017. Its up 0.06, from 1.03 in 2017Q3. It increased, as 30 investors sold Jazz Pharmaceuticals plc shares while 89 reduced holdings. 49 funds opened positions while 81 raised stakes. 52.98 million shares or 1.12% less from 53.58 million shares in 2017Q3 were reported. The Denmark-based C Grp A S has invested 0.1% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Northern accumulated 219,565 shares. Sector Pension Investment Board holds 0% or 4,600 shares in its portfolio. Bessemer Group Inc Inc, a New Jersey-based fund reported 81 shares. D E Shaw And Co Incorporated accumulated 175,516 shares. Ellington Mgmt Group Lc invested in 4,700 shares or 0.1% of the stock. Moreover, Sumitomo Mitsui Asset Mgmt Company has 0.01% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 4,169 shares. Illinois-based Dearborn Prns Limited Liability has invested 0.02% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Livforsakringsbolaget Skandia Omsesidigt reported 0.3% stake. Boston Advsrs Limited Liability Com holds 3,240 shares or 0.01% of its portfolio. Gateway Inv Advisers Lc stated it has 0.06% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). 4,244 were accumulated by Lincoln Natl Corp. Moreover, Raymond James Services Advisors Inc has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Aviance Prtn Limited Liability Company owns 0.72% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 16,098 shares. Hightower Advsrs Ltd Liability Co stated it has 10,867 shares or 0.01% of all its holdings.

Among 16 analysts covering New Relic Inc (NYSE:NEWR), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. New Relic Inc had 48 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Monday, April 2 by Needham. The stock of New Relic, Inc. (NYSE:NEWR) earned “Buy” rating by Guggenheim on Tuesday, December 15. The company was maintained on Wednesday, February 7 by Guggenheim. KeyBanc Capital Markets maintained New Relic, Inc. (NYSE:NEWR) rating on Monday, March 19. KeyBanc Capital Markets has “Overweight” rating and $86 target. The rating was upgraded by Morgan Stanley on Thursday, September 10 to “Overweight”. On Wednesday, September 9 the stock rating was initiated by First Analysis with “Overweight”. Cowen & Co maintained the shares of NEWR in report on Wednesday, February 7 with “Buy” rating. Morgan Stanley downgraded New Relic, Inc. (NYSE:NEWR) rating on Thursday, July 20. Morgan Stanley has “Equal-Weight” rating and $48 target. The firm earned “Overweight” rating on Wednesday, November 8 by KeyBanc Capital Markets. The rating was maintained by UBS with “Neutral” on Friday, August 4.

Analysts await New Relic, Inc. (NYSE:NEWR) to report earnings on August, 2. They expect $-0.12 earnings per share, up 55.56% or $0.15 from last year’s $-0.27 per share. After $-0.10 actual earnings per share reported by New Relic, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>